Hospital for Sick Children
Toronto, Ontario, Canada
Location contact
Brandon Zanette, PhD
PRINCIPAL_INVESTIGATOR
Sharon Braganza, MSC, CCRP
CONTACT
416-813-7654 ext. 307937
Sheryl Hewko, MSc, RN
CONTACT
NCT Number: NCT07454681
This study is being done to determine whether MRI can produce high quality lung and airway images in healthy and CF patients and if MRI can be used to evaluate size and shape of the airways with computer assistance. This study will also repeat MRI experiments two years after the initial MRI scan to see if changes to airway size and shape are seen over time. In a subset of participants, we will investigate whether MRI results are repeatable and reproducible in the short-term one week after the initial MRI visit. This study will help understand if MRI based measurements of airway size and shape can be used as a monitoring tool that does not use x-ray radiation in patients with CF.
Trial opening soon.
Get Notified6 year–18 year
All sexes
Observational
Toronto, Ontario, Canada
Brandon Zanette, PhD
PRINCIPAL_INVESTIGATOR
Sharon Braganza, MSC, CCRP
CONTACT
416-813-7654 ext. 307937
Sheryl Hewko, MSc, RN
CONTACT
Early CF disease in the lungs is characterized by repeated infection which can alter dimensions of the airways , especially abnormal dilation of the airways (bronchiectasis) Airway tree mapping is a form of quantitative imaging that investigates segmentation and dimensionality of the upper airways. CT detects utilized to characterize airway dimension in adults with COPD, but involves ionizing radiation. Unexplored in children.
MRI: Non-invasive, radiation-free, ideal for longitudinal monitoring. However, struggles with lung imaging due to low signal intensity, short T2 relaxation times, and motion artifacts Advanced ultrashort echo time (UTE) MRI enables high-resolution airway imaging with motion correction for free-breathing airway imaging. May permit airway tree mapping in children while obviating ionizing radiation risk.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Group 1
Inclusion criteria
Exclusion criteria
Group 2 Inclusion Criteria
Exclusion criteria
UTE lung MRI with various parameters will be done to determine optimal image quality for airway segmentation. The average scanning time for each sequence is in the order of 10 minutes.
Lung clearance index (LCI) will be determined by nitrogen multiple breath washout using the Exhalyzer D for measurement of inert gas washout. LCI measures will be taken in triplicate to ensure reproducibility.
Time frame: Baseline (Visit 1A); Optional 1-week repeatability visit (Visit 1B) & 2-year follow-up (Visit 2A)
Quantitative measurement of airway lumen diameter (millimeters) across airway generations 1-6 using UTE MRI airway tree segmentation.
Time frame: Baseline (Visit 1A); Optional 1-week repeatability visit (Visit 1B) & 2-year follow-up (Visit 2A)
LCI measured with nitrogen Multiple Breath Washout (MBW).
Contact information is provided by the study sponsor or research team.
The Hospital for Sick Children
Other
Development of Magnetic Resonance Imaging Airway Segmentation to Assess and Monitor Cystic Fibrosis Lung Disease
Acronym: UTE Airway MR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07696338
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Birmingham, Alabama, United States
View Trial DetailsNCT07692594
Cardiovascular (CV) Risk, Cardiovascular Diseases
Liverpool, United Kingdom
View Trial DetailsNCT07688070
Abnormal Glucose Tolerance, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Boston, Massachusetts, United States
View Trial DetailsNCT07665203
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
View Trial Details